Whether another biobetter after Nexviazyme will be receiving premium pricing in Korea is gaining attention.

According to industry sources on the 30th, Roche Korea’s subcutaneous fixed-dose combination injection Phesgo (pertuzumab, trastuzumab) that combined ‘Perjeta’ and ‘Herceptin’ has passed the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation committee review.

Therefore, after undergoing the Drug Reimbursement Evaluation Committee review, Roche will sign agreements with the National Health Insurance Service regarding the supply and quality control obligations for Phesgo.

If successfully listed, Phesgo will become the first anticancer